MYD88 and cancer: In a mouse model of azoxymethane/dextran sodium sulfate (AOM/DSS)—induced (CAC) in combination with TJ-M2010-5 administration, the anti-inflammation-related cancer effect of MyD88 inhibitor was investigated in vivo, and MyD88 inhibitors may be a promising therapeutic modality for treating patients with CAC [55].